Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples